IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

IDEXX Laboratories executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference. The outlook is supported by veterinary-diagnostics demand, product innovation, commercial investment, and a recurring-revenue business model; no new financial targets or material guidance changes were disclosed.